Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XBiotech Faces Uphill Task With Xilonix

Executive Summary

Texas-based biotech XBiotech is going to find it tough to persuade clinicians and regulators about the usefulness of it its human antibody Xilonix after it discontinued the second Phase III study of the human antibody, in US colorectal cancer patients.

You may also be interested in...



XBiotech Says CHMP ‘No’ Was A Surprise, Despite The Signs

Where now for XBiotech? The US firm says that despite a big setback for Xilonix in the EU, it will continue to develop the product in oncology.

Three CHMP Negative Opinions ‒ But Who Got A Boon?

The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?

Verona Details COPD Opportunity For Ensifentrine

Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.

Topics

Related Companies

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel